MDR1 P-glycoprotein

Y., Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein, Pharm. Res. 2001, 38, 1660-1668. 

Rao W, Dahlheimer JL, Bardgett ME, Snyder AZ, Finch RA, Sartorelli AC et al. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidmg resistance-associated protein contribute to the blood-cerebrospinalfluid drug-permeability barrier. Proc Natl Acad Sci USA 1999 96(7) 3900-3905. 

Van Helvoort, A., Smith, A. J., Sprang, H. et al. MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell 87 507-17,1996. 

Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein) recent advances and clinical relevance. Clin Pharm Ther 2004 75 13-33. 

Sparreboom A, Planting AS, Jewell RC, et al. Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein. Anticancer Drugs 1999 10(8) 719-728. 

Schinkel AH, Kemp S, Dolle M, et al. N-glycosylation and deletion mutants of the human MDR1 P-glycoprotein. J Biol Chem 1993 268(10) 7474-7481. 

Chambers TC, Germann UA, Gottesman MM, et al. Bacterial expression of the linker region of human MDR1 P-glycoprotein and mutational analysis of phosphorylation sites. Biochemistry 1995 34(43) 14156-14162. 

Fig. 7 Possible model for the molecular mechanism of multidrug transporters. MDR1-P-glycoprotein (substrates are recognized in, or near to the membrane lipid phase). Abbreviations hD hydrophobic drugs, PL Phospholipids. (Reproduced from [4])...

Pichler A, Zelcer N, Prior JL, Kuil AJ, Piwnica-Worms D. In vivo RNA interference-mediated ablation of MDR1 P-glycoprotein. Clin Cancer Res 2005 11 4487-94. 

Brenn A, Grube M, Peters M, Fischer A, Jedlitschky G, Kroemer HKet al (2011) Beta-amyloid downregulates MDR1 -P-glycoprotein (Abcbl) expression at the blood-brain barrier in mice. Int J Alzheimers Dis 2011 690121. doi 10.4061/2011/690121... 

Norris MD, De Graaf D, Haber M, Kavallaris M, Madafiglio J, Gilbert J et al (1996) Involvement of MDR1 P-glycoprotein in multifactorial resistance to methotrexate. Int J Cancer 65 613-619... 

Brimer,C.,Dalton,J.T.,Zhu,Z., Schuetz,J., Yasuda, K., Vanin, E., Relling, M.V., Lu, Yi. and Schuetz, E.G. (2000) Creation of polarized cells coexpressing CYP3A4, NADPH cytochrome P450 reductase and MDR1 /P-glycoprotein. Pharmaceutical Research, 17, 803-810. 

Luker, G.D., T.P. Flagg, Q. Sha, K.E. Luker, C.M. Pica, C.G. Nichols and D. Piwnica-Worms. MDR1 P-glycoprotein reduces influx of substrates without affecting membrane potential. J. Biol. Chem. 276 49053-49060, 2001. 

Oude Elferink, R.P.J. and J. Zadina. MDR1 P-glycoprotein transports endogenous opioid peptides. Peptides 22 2015-2020, 2001. 

---